RS52219B - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis

Info

Publication number
RS52219B
RS52219B RS20120161A RSP20120161A RS52219B RS 52219 B RS52219 B RS 52219B RS 20120161 A RS20120161 A RS 20120161A RS P20120161 A RSP20120161 A RS P20120161A RS 52219 B RS52219 B RS 52219B
Authority
RS
Serbia
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
RS20120161A
Other languages
Serbian (sr)
Inventor
Giampiero De Luca
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa. filed Critical Merck Serono Sa.
Priority claimed from PCT/EP2005/056954 external-priority patent/WO2006067141A1/en
Publication of RS52219B publication Critical patent/RS52219B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)

Abstract

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
RS20120161A 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis RS52219B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
RS52219B true RS52219B (en) 2012-10-31

Family

ID=34930135

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120161A RS52219B (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Country Status (10)

Country Link
AT (1) ATE547106T1 (en)
DK (1) DK1827461T3 (en)
ES (4) ES2428741T3 (en)
HU (1) HUE035859T2 (en)
LT (1) LT2805723T (en)
ME (1) ME01333B (en)
PT (3) PT3332789T (en)
RS (1) RS52219B (en)
SI (1) SI1827461T1 (en)
UA (1) UA96260C2 (en)

Also Published As

Publication number Publication date
ES2428741T3 (en) 2013-11-11
PT3332789T (en) 2022-07-05
UA96260C2 (en) 2011-10-25
ES2666146T3 (en) 2018-05-03
PT1827461E (en) 2012-05-07
PT2805723T (en) 2018-01-25
DK1827461T3 (en) 2012-03-26
ES2495392T3 (en) 2014-09-17
HUE035859T2 (en) 2018-05-28
ME01333B (en) 2013-12-20
SI1827461T1 (en) 2012-05-31
ES2382554T3 (en) 2012-06-11
LT2805723T (en) 2018-02-12
ATE547106T1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
SG160391A1 (en) Cladribine regimen for treating multiple sclerosis
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
TW200508214A (en) Novel compounds
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2009006742A (en) Novel compounds.
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
WO2006063841A3 (en) Trycyclic heterocycles, their manufacture and use as pharmaceutical agents
RS20090083A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta -mimetics
MY141025A (en) Dose forms
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
WO2003082853A8 (en) New compounds
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200621259A (en) Chemical compounds
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
MY148125A (en) Compounds
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
TW200639156A (en) New compounds
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
MY146802A (en) Novel drugs for treating respiratory diseases
UA91694C2 (en) Use of emodepside and pf1022 for prevention of vertical endoparasite infections
TW200634002A (en) Chemical compounds
UA104281C2 (en) Antitumoral peptide analogs, process for the preparation thereof and pharmaceutical composition based thereon
BRPI0618370A2 (en) aerosol drug formulation, drug use and inhalation kit
PT2805723T (en) Cladribine regimen for treating multiple sclerosis